A research note from Jarden has valued NZX-listed biotech Pacific Edge at double its current share price, citing the long-term commercial potential of its bladder cancer diagnostic technology, just need access to read full article - https://www.facebook.com/NBROnline/
- Forums
- ASX - By Stock
- PEB
- Analysts pick Pacific Edge to double in value
Analysts pick Pacific Edge to double in value
Featured News
Add PEB (NZSX) to my watchlist
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online